Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered Once-daily for 42 Days to Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy
Conditions
Interventions
Placebo
Lusutrombopag
Locations
19
United States
Investigator
Anaheim, California, United States
Investigator
Los Angeles, California, United States
Investigator
Washington D.C., District of Columbia, United States
Investigator
Boynton Beach, Florida, United States
Investigator
Jacksonville, Florida, United States
Investigator
Atlanta, Georgia, United States
Start Date
March 18, 2010
Primary Completion Date
November 24, 2010
Completion Date
November 24, 2010
Last Updated
March 18, 2021
NCT07294365
NCT07175493
NCT06888960
NCT07095127
NCT06371417
NCT06853444
Lead Sponsor
Shionogi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions